Skip to main content
Royalty, Zealand to enter deal on diabetes drugs

Royalty Pharma will acquire Zealand Pharma's royalty rights and potential commercial milestones worth $85 million tied to Lyxumia/Adlyxin, or lixisenatide, and Soliqua/Suliqua, or insulin glargine and lixisenatide injection, both indicated to treat diabetes type 2. Royalty will pay $205 million in the deal.

Full Story: